medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2016, Number 3

<< Back Next >>

An Med Asoc Med Hosp ABC 2016; 61 (3)

Calcium pyrophosphate deposition disease: 60 Mexican patients

Canoso JJ

Language: Spanish
References: 22
Page: 188-194
PDF size: 267.62 Kb.


ABSTRACT

Objective: There are no previous Mexican reports of calcium pyrophosphate deposition disease. Material and methods: The clinical records of 7,200 patients seen by the author between 1995 and 2015 were reviewed. Cases of calcium pyrophosphate deposition disease were identified by means of a «Windows search» using the appropriate search terms. Patients were classified clinically, by the results of X-ray studies, and according to the findings in the synovial fluid analysis. Results: There were 60 patients with calcium pyrophosphate deposition disease, 39 female (median age 76), and 21 male (median age 71). Twenty-two patients had acute arthritis (pseudogout), 20 had calcium pyrophosphate deposition disease plus osteoarthritis (OA), 16 had chronic arthritis, and two had calcium pyrophosphate crystals in incidental effusions. Three patients had a destructive arthropathy. Despite the female predominance, acute arthritis occurred equally in both sexes. Chondrocalcinosis was present in 59 patients. Forty patients had a joint aspiration, and in 37 of them, calcium pyrophosphate crystals were found in synovial fluid. Of these, in three, urate crystals were concurrently seen. Rheumatoid arthritis had been erroneously diagnosed in five of the patients. Conclusions: Calcium pyrophosphate deposition disease occurs in Mexico and may predominate in European ascent individuals. When calcium pyrophosphate crystals are identified in acute arthritis and in exacerbations of osteoarthritis, a favorable course may be predicted as these episodes respond well to low-dose oral steroids or a depo-steroid injection. Long-term prophylaxis with colchicine may prevent recurrences of pseudogout and decrease pain in chronic calcium pyrophosphate deposition disease.


REFERENCES

  1. Žitňan D, Sit’Aj Š. Chondrocalcinosis articularis section L clinical and radiological study. Ann Rheum Dis. 1963; 22: 142-152.

  2. McCarty DJ, Kohn NN, Faires JS. The significance of calcium phosphate crystals in the synovial fluid of arthritic patients: the “pseudogout syndrome”. Clinical aspects. Ann Inter Med. 1962; 56: 711-737.

  3. Reginato AJ. Calcium pyrophosphate dihydrate gout and other crystal deposition diseases. Curr Opin Rheumatol. 1991; 3: 676-683.

  4. Rull M. Calcium crystal-associated diseases and miscellaneous crystals. Curr Opin Rheumatol. 1997; 9: 274-279.

  5. Rangel SF, López OA, Canoso JJ. Podagra calcárea. An Med Asoc Med Hosp ABC. 1999; 44: 173-176.

  6. Bird HA, Tribe CR, Bacon PA. Joint hypermobility leading to osteoarthrosis and chondrocalcinosis. Ann Rheum Dis. 1978; 37: 203-211.

  7. Abhishek A, Doherty M. Epidemiology of calcium pyrophosphate crystal arthritis and basic calcium phosphate crystal arthropathy. Rheum Dis Clin North Am. 2014; 40: 177-191.

  8. Richardson BC, Chafetz NI, Ferrell LD, Zulman JI, Genant HK. Hereditary chondrocalcinosis in a Mexican-American family. Arthritis Rheum. 1983; 26: 1387-1396.

  9. Sanmartí R, Serrarols M, Galinsoga A, Pañella D, Kanterewicz E, Brugués J. Enfermedades asociadas con condrocalcinosis articular; Análisis de una serie de 95 casos. Med Clin (Barc). 1993; 101: 294-297.

  10. Egan MW, Canoso JJ. Relative frequency of gout and pseudogout. Arthritis Rheum. 1979; 22: 428-429.

  11. Maravic M, Ea HK. Hospital burden of gout, pseudogout and other crystal arthropathies in France. Joint Bone Spine. 2015; 82: 326-329.

  12. Reginato AJ, Hollander JL, Martinez V, Valenzuela F, Schiapachasse V, Covarrubias E et al. Familial chondrocalcinosis in the Chiloe Islands, Chile. Ann Rheum Dis. 1975; 34: 260-268.

  13. Pons-Estel BA, Gimenez C, Sacnun M, Gentiletti S, Battagliotti CA, de la Pena LS et al. Familial osteoarthritis and Milwaukee shoulder associated with calcium pyrophosphate and apatite crystal deposition. J Rheumatol. 2000; 27: 471-480.

  14. Amigo MC, Canoso JJ. Detección de cristales de urato monosódico en líquido sinovial en la práctica clínica: barreras y oportunidades. An Med Asoc Med Hosp ABC. 2016; 61 (3) : 173-176.

  15. Williams CJ, Pendleton A, Bonavita G, Reginato AJ, Hughes AE, Peariso S et al. Mutations in the amino terminus of ANKH in two US families with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum. 2003; 48: 2627-2631.

  16. Pendleton A, Johnson MD, Hughes A, Gurley KA, Ho AM, Doherty M et al. Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet. 2002; 71: 933-940.

  17. Mitton-Fitzgerald E, Gohr CM, Bettendorf B, Rosenthal AK. The role of ANK in calcium pyrophosphate deposition disease. Curr Rheumatol Rep. 2016; 18: 25.

  18. Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA, Jansen TL et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011; 70: 571-575.

  19. Swan A, Heywood B, Chapman B, Seward H, Dieppe P. Evidence for a causal relationship between the structure, size, and load of calcium pyrophosphate dihydrate crystals, and attacks of pseudogout. Ann Rheum Dis. 1995; 54: 825-830.

  20. Finckh A, Mc Carthy GM, Madigan A, Van Linthoudt D, Weber M, Neto D et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014; 16: 458. doi: 10.1186/s13075-014-0458-4.

  21. Aran S, Malekzadeh S, Seifirad S. A double-blind randomized controlled trial appraising the symptom-modifying effects of colchicine on osteoarthritis of the knee. Clin Exp Rheumatol. 2011; 29: 513-518.

  22. Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol. 1986; 13: 804-805.




2020     |     www.medigraphic.com